Ezetimibe for Primary Hypercholesterolemia and Mixed Dyslipidemia
Ezetimibe 10 mg orally once daily is the standard dose for adults with primary hypercholesterolemia or mixed dyslipidemia, used either as monotherapy when statins are not tolerated or in combination with statins when LDL-C goals are not achieved on statin therapy alone. 1
Dosing
- Standard dose: 10 mg orally once daily, with or without food 1
- Administer either ≥2 hours before or ≥4 hours after bile acid sequestrants if used in combination 1
- Assess LDL-C as early as 4 weeks after initiation 1
- The tablet should be swallowed whole 2
Important note: While one study suggested 5 mg (splitting a 10 mg tablet) may be clinically equivalent to 10 mg 3, the FDA-approved dose remains 10 mg daily, and this is what should be prescribed in standard practice 1.
Indications
Primary indications for ezetimibe include: 1
- Primary hyperlipidemia: As adjunct to diet, either in combination with a statin or alone when additional LDL-C lowering is not possible
- Mixed hyperlipidemia: In combination with fenofibrate as adjunct to diet
- Heterozygous familial hypercholesterolemia (HeFH): In combination with a statin in adults and pediatric patients ≥10 years
- Homozygous familial hypercholesterolemia (HoFH): In combination with a statin and other LDL-C lowering therapies in adults and pediatric patients ≥10 years
- Homozygous familial sitosterolemia: As adjunct to diet in adults and pediatric patients ≥9 years
Risk-Stratified Approach to Adding Ezetimibe
For patients at very high cardiovascular risk: Add ezetimibe to maximally tolerated statin therapy when LDL-C remains ≥70 mg/dL (1.8 mmol/L) 2. The European Society of Cardiology recommends combination with ezetimibe if LDL goals (55 mg/dL for very high risk) are not achieved with maximum tolerated statin dose 2.
For patients at high cardiovascular risk: There is a strong recommendation for adding ezetimibe when LDL-C goals are not met on statin therapy alone 2.
For patients at low cardiovascular risk: There is a strong recommendation AGAINST adding ezetimibe, as the burden outweighs benefits 2.
For primary prevention: Consider adding ezetimibe if maximum tolerated statin dose does not achieve non-HDL cholesterol reduction >40% of baseline after 3 months 2.
Expected Efficacy
- Monotherapy: Reduces LDL-C by approximately 15-20% 2, 4, 5
- Combination with statin: Provides incremental LDL-C reduction of approximately 25% 2
- Total combination effect with low-dose statin: Can achieve 47-58% LDL-C reduction 6, 7
- Increases HDL-C by 2.5-5% 4
- LDL-C reduction occurs early (within 2-4 weeks) and persists throughout treatment 5, 6
Contraindications
Absolute contraindications: 1
- Hypersensitivity to ezetimibe or any excipient
- When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe is contraindicated in patients for whom those agents are contraindicated (refer to their prescribing information)
Relative contraindications/precautions: 2
- Not recommended in patients with moderate to severe hepatic impairment 2
- Avoid use during pregnancy (no safety data in humans) 2, 1
- Avoid use during lactation 2, 1
Monitoring
Hepatic Monitoring
- Monitor liver enzymes (ALT/AST) before and during treatment based on statin monitoring recommendations when used in combination 2, 1
- Persistent elevations in hepatic transaminases may occur with concomitant statin therapy 2
- Consider withdrawal if ALT or AST ≥3× ULN persist 1
Muscle Monitoring
- Monitor for signs and symptoms of myopathy and rhabdomyolysis 2, 1
- Most cases of rhabdomyolysis in post-marketing reports occurred in patients taking a statin or fibrates concomitantly 1
- If myopathy is suspected, discontinue ezetimibe and other concomitant medications as appropriate 1
Lipid Monitoring
- Assess LDL-C as early as 4 weeks after initiating therapy 1
- Continue monitoring at clinically appropriate intervals to assess goal achievement 2
Other Monitoring
- Ezetimibe does not affect absorption of fat-soluble vitamins, so routine vitamin monitoring is not required 4, 5
- Does not affect cortisol production 8
Drug Interactions
Key interactions to avoid or manage: 2
- Cyclosporine: Significant interaction; use with caution
- Fibrates: Increased risk of cholelithiasis; monitor closely
- Bile acid sequestrants: Administer ezetimibe ≥2 hours before or ≥4 hours after
- Avoid concomitant simvastatin >20 mg daily or pravastatin >40 mg daily when using combination products containing ezetimibe 2
Adverse Effects
Common adverse effects (≥2% and greater than placebo): 1
- Upper respiratory tract infection
- Diarrhea
- Arthralgia
- Sinusitis
- Pain in extremities
- Fatigue
- Influenza
When combined with statins: Nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea 2
The safety profile is generally similar to placebo when used as monotherapy 4, 8, 9, 5, making it well-tolerated compared to other lipid-lowering agents.
Cardiovascular Outcomes Evidence
Two major trials demonstrate cardiovascular benefit: 2
- IMPROVE-IT: Addition of ezetimibe to moderate-intensity statin in patients with recent acute coronary syndrome resulted in incremental LDL-C lowering and reduced the primary composite endpoint of CV death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke over median 6-year follow-up
- SHARP: Simvastatin plus ezetimibe reduced LDL-C and reduced first major ASCVD events in patients with chronic kidney disease over median 4.9-year follow-up
Clinical Pearls and Pitfalls
Common pitfalls to avoid:
- Do not use ezetimibe in low-risk patients where burden exceeds benefit 2
- Remember to space administration from bile acid sequestrants by at least 2 hours before or 4 hours after 1
- Do not assume all patients need aggressive LDL-C lowering—risk stratification is essential 2
- When combining with statins, follow statin-specific monitoring protocols for liver enzymes 2
Advantages in clinical practice: